Johnson & Johnson $JNJ Shares Sold by Janney Montgomery Scott LLC

Key Points

• Janney Montgomery Scott LLC has reduced its stake in Johnson & Johnson by 3.7%, now holding approximately 1.29 million shares worth about $197.5 million.
• Johnson & Johnson reported quarterly earnings of $2.77 per share, surpassing analyst estimates, with a revenue of $23.74 billion, a 5.8% increase year-over-year.
• The company announced a quarterly dividend of $1.30 per share, reflecting a dividend yield of 2.8%, with a payout ratio of 55.61%.

Janney Montgomery Scott LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,293,106 shares of the company's stock after selling 50,034 shares during the quarter. Janney Montgomery Scott LLC owned approximately 0.05% of Johnson & Johnson worth $197,522,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. Nuveen LLC acquired a new stake in shares of Johnson & Johnson in the 1st quarter valued at about $1,369,188,000. Bank of New York Mellon Corp lifted its stake in Johnson & Johnson by 26.4% in the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock valued at $3,844,580,000 after buying an additional 4,842,582 shares during the last quarter. Pacer Advisors Inc. boosted its holdings in shares of Johnson & Johnson by 1,382.0% in the first quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company's stock valued at $502,509,000 after acquiring an additional 2,825,626 shares during the period. Assenagon Asset Management S.A. grew its position in shares of Johnson & Johnson by 159.6% during the second quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company's stock worth $635,327,000 after acquiring an additional 2,557,388 shares during the last quarter. Finally, Kingstone Capital Partners Texas LLC acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at $401,420,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Up 2.1%

Shares of NYSE JNJ opened at $185.40 on Wednesday. The stock has a market capitalization of $446.51 billion, a price-to-earnings ratio of 19.83, a price-to-earnings-growth ratio of 2.31 and a beta of 0.40. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $185.99. The firm has a 50-day moving average price of $175.11 and a 200 day moving average price of $162.34. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company's revenue for the quarter was up 5.8% on a year-over-year basis. During the same period last year, the firm earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.8%. Johnson & Johnson's dividend payout ratio is 55.61%.

Analyst Ratings Changes

A number of brokerages recently weighed in on JNJ. Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Bank of America increased their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research note on Thursday, July 17th. Barclays raised their price target on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Guggenheim raised Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Finally, The Goldman Sachs Group lifted their target price on Johnson & Johnson from $185.00 to $186.00 and gave the company a "buy" rating in a research note on Friday, September 19th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $181.40.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company's stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.